ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 85

Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population

Naoyuki Tsuchiya1, Narumi Hasebe1, Ken-ei Sada2, Shigeto Kobayashi3, Hidehiro Yamada4, Hiroshi Furukawa5, Kunihiro Yamagata6, Takayuki Sumida7, Nobuyuki Miyasaka8, Seiichi Matsuo9, Shigeto Tohma5, Shoichi Ozaki10, Hiroshi Hashimoto11, Hirofumi Makino2, Masayoshi Harigai12 and Aya Kawasaki1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 6Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 7Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 8Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 9Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 10Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 11Juntendo University School of Medicine, Tokyo, Japan, 12Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANCA, genetics, human leukocyte antigens (HLA), myeloperoxidase (MPO) and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics, Genomics and Proteomics I

Session Type: Abstract Submissions (ACR)

Background/Purpose

Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority of AAV patients are positive for myeloperoxidase (MPO) – ANCA. In studies with a small sample size, we previously reported significant association of HLA-DRB1*09:01-DQB1*03:03, a haplotype common in Asians but rare in other populations, with MPO-ANCA positive AAV (Tsuchiya et al., 2003; Tsuchiya et al., 2006). In the present study, we substantially increased the sample size, and compared HLA-DRB1 associations among AAV subgroups, and also made an attempt to detect other DRB1alleles associated with risk or protection.

Methods

HLA-DRB1genotypes were determined by using WAK Flow HLA-typing kit (Wakunaga, Hiroshima, Japan) in 356 Japanese AAV and 596 healthy controls. Among the patients, 220 were classified as microscopic polyangiitis (MPA), 69 as granulomatosis with polyangiitis (GPA), 35 as eosinophilic granulomatosis with polyangiitis (EGPA), and 32 were unclassifiable, according to the European Medicines Agency algorithm. Among all patients, 300 were positive for myeloperoxidase (MPO)-ANCA and 41 for proteinase 3 (PR3)-ANCA. The second risk allele and protective allele were examined by relative predispositional effects (RPE) method. Bonferroni correction was employed to correct for the number of compared alleles.

Results

Positive association of DRB1*09:01 carrier frequency was confirmed in MPA (P=0.0036, Pc=0.0076, odds ratio [OR] 1.81). In addition, significant negative association with DRB1*13:02 was detected in MPA (P=0.001, Pc=0.0244, OR 0.43). In GPA, tendency toward positive association was detected in DRB1*08:02 (P=0.031, Pc=0.65, OR 2.56) and negative association in DRB1*13:02 (P=0.037, Pc=0.77, OR 0.38). The associations were more striking when the patients were classified according to the specificity of ANCA. In MPO-ANCA positive patients, DRB1*09:01 was increased (P=2.3×10-5, Pc=4.8×10-4, OR 1.89), while DRB1*13:02 was decreased (P=3.7×10-5, Pc=7.8×10-4, OR 0.38). RPE method confirmed negative association of DRB1*13:02 (PRPE=7.3×10-4, ORRPE 0.47), and also suggested DRB1*08:02 as the second risk allele (PRPE=0.025, ORRPE 1.82). In PR3-ANCA positive patients, suggestive association was observed for DRB1*11:01 (P=0.021, Pc=0.65, OR 3.80), but not for DRB1*09:01 (P=0.86, OR 1.02). Genotype comparison suggested that carriage of DRB1*13:02 cancels the risk of DRB1*09:01 to MPO-ANCA positive AAV in *09:01/*13:02 heterozygotes.

Conclusion

DRB1*09:01 is associated with MPO-ANCA positive, but not with PR3-ANCA positive, AAV. Because DRB1*09:01 is a very common HLA-DRB1 allele in East Asian bur rare in European populations, such a difference in the genetic background may be associated with the difference in the prevalence of MPO-positive and PR3-positive AAV in both populations. In addition, DRB1*13:02 was identified as a protective allele against MPO-ANCA positive AAV.


Disclosure:

N. Tsuchiya,
None;

N. Hasebe,
None;

K. E. Sada,
None;

S. Kobayashi,
None;

H. Yamada,
None;

H. Furukawa,
None;

K. Yamagata,
None;

T. Sumida,
None;

N. Miyasaka,
None;

S. Matsuo,
None;

S. Tohma,
None;

S. Ozaki,
None;

H. Hashimoto,
None;

H. Makino,
None;

M. Harigai,
None;

A. Kawasaki,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/protective-association-of-hla-drb11302-against-mpo-anca-positive-anca-associated-vasculitis-in-a-japanese-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology